Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Pain ; 118(1-2): 97-111, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16213091

ABSTRACT

Reactivation of latent varicella zoster virus (VZV) within sensory trigeminal and dorsal root ganglia (DRG) neurons produces shingles (zoster), often accompanied by a chronic neuropathic pain state, post-herpetic neuralgia (PHN). PHN persists despite latency of the virus within human sensory ganglia and is often unresponsive to current analgesic or antiviral agents. To study the basis of varicella zoster-induced pain, we have utilised a recently developed model of chronic VZV infection in rodents. Immunohistochemical analysis of DRG following VZV infection showed the presence of a viral immediate early gene protein (IE62) co-expressed with markers of A- (neurofilament-200; NF-200) and C- (peripherin) afferent sensory neurons. There was increased expression of neuropeptide Y (NPY) in neurons co-expressing NF-200. In addition, there was an increased expression of alpha2delta1 calcium channel, Na(v)1.3 and Na(v)1.8 sodium channels, the neuropeptide galanin and the nerve injury marker, Activating Transcription Factor-3 (ATF-3) as determined by Western blotting in DRG of VZV-infected rats. VZV infection induced increased behavioral reflex responsiveness to both noxious thermal and mechanical stimuli ipsilateral to injection (lasting up to 10 weeks post-infection) that is mediated by spinal NMDA receptors. These changes were reversed by systemic administration of gabapentin or the sodium channel blockers, mexiletine and lamotrigine, but not by the non-steroidal anti-inflammatory agent, diclofenac. This is the first time that the profile of VZV infection-induced phenotypic changes in DRG has been shown in rodents and reveals that this profile appears to be broadly similar (but not identical) to changes in other neuropathic pain models.


Subject(s)
Amines/pharmacology , Cyclohexanecarboxylic Acids/pharmacology , Ganglia, Spinal/virology , Herpesvirus 3, Human/drug effects , Mexiletine/pharmacology , Neuralgia/etiology , Sodium Channels/drug effects , Triazines/pharmacology , Virus Latency/physiology , gamma-Aminobutyric Acid/pharmacology , Amines/therapeutic use , Animals , Anticonvulsants/pharmacology , Anticonvulsants/therapeutic use , Behavior, Animal/drug effects , Behavior, Animal/physiology , Cyclohexanecarboxylic Acids/therapeutic use , Disease Models, Animal , Fluorescent Antibody Technique , Gabapentin , Galanin/metabolism , Ganglia, Spinal/metabolism , Ganglia, Spinal/physiopathology , Herpes Zoster/metabolism , Herpes Zoster/prevention & control , Herpes Zoster/virology , Herpesvirus 3, Human/physiology , Immediate-Early Proteins/metabolism , Immunohistochemistry , Lamotrigine , Mexiletine/therapeutic use , Neuralgia/prevention & control , Neuralgia, Postherpetic/prevention & control , Neuralgia, Postherpetic/virology , Neurons, Afferent/metabolism , Neuropeptide Y/metabolism , Rats , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/physiology , Reflex/drug effects , Reflex/physiology , Sodium Channels/metabolism , Trans-Activators/metabolism , Triazines/therapeutic use , Viral Envelope Proteins/metabolism , gamma-Aminobutyric Acid/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...